Hint mode is switched on Switch off

Mirum Pharmaceuticals, ordinary share
MIRM, US6047491013

Add a stock to WL
Choose all Reset all
Mirum Pharmaceuticals, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug ...
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Mirum Pharmaceuticals, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    MIRM
  • Placement
    18.07.2019
  • Lock up period
    180
  • Number of papers
    5,000,000
  • Volume of raised funds
    75 mln USD
  • Placement share
    21.72%
  • Final placement price
    15 USD
  • Price change since placement date
    523.6%
  • By capitalization
    345.24 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    MIRM
  • Placement
    09.01.2020
  • Lock up period
    180
  • Number of papers
    2,400,000
  • Volume of raised funds
    48 mln USD
  • Placement share
    9.45%
  • Final placement price
    20 USD
  • Price change since placement date
    367.7%
  • By capitalization
    507.8 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    MIRM
  • Placement
    15.12.2020
  • Lock up period
    180
  • Number of papers
    3,750,000
  • Volume of raised funds
    75 mln USD
  • Placement share
    12.82%
  • Final placement price
    20 USD
  • Price change since placement date
    367.7%
  • By capitalization
    585.01 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2025
I q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
II q eng
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

19/05/2026 New issue: Mirum Pharmaceuticals issued bonds in the amount of USD 600 mln maturing in 2032
12/05/2026 Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
12/05/2026 Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
12/05/2026 Mirum Pharmaceuticals: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An, Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibits
05/05/2026 Mirum Pharmaceuticals (NASDAQ: MIRM) Surges on Positive Volixibat Clinical Trial Results and Analyst Price Target Hike
All organization news

Domestic and international bonds of the issuer

Holders

Industry Leaders

Registration is required to get access.